• 0Shopping Cart
AmideBio LLC
  • ABOUT
  • TEAM
    • Management and Operations
    • Board of Directors
    • Advisory Board
  • SCIENCE
    • Therapeutic Pipeline
    • Discovery
    • Manufacturing
  • PRODUCTS
    • Amyloid Peptides
    • Amyloid Kits and Buffers
    • Bowman-Birk Inhibitors
    • Brazzeins
    • Proinsulin
    • Toxins and Knottins
    • Custom Product Inquiry
    • Request Quote
  • NEWS
  • SUPPORT
    • CONTACT
    • Frequently Asked Questions
    • Application Notes
    • Inquiry Form
  • My Account
    • Checkout
    • Login
  • Search
  • Menu
Blog - Latest News
You are here: Home / Privacy Policy / AmideBio_Press_Release_ C. Stanley CHOP 112217

AmideBio_Press_Release_ C. Stanley CHOP 112217

2017-11-23/by Admino

Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on Google+
  • Share on Pinterest
  • Share on Linkedin
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail
https://www.amidebio.com/wp-content/uploads/2016/07/ABlogo3-300x138.gif 0 0 Admino https://www.amidebio.com/wp-content/uploads/2016/07/ABlogo3-300x138.gif Admino2017-11-23 00:50:072017-11-23 00:50:07AmideBio_Press_Release_ C. Stanley CHOP 112217

COMPANY NEWS

  • AMIDEBIO Granted Orphan Drug Designation by FDA for Novel Solution Stable Glucagon2020-04-22 - 17:35

    AmideBio, LLC, a privately held biopharmaceutical company, announced today that the US Food and Drug Administration (FDA) Office of Orphan Products Development granted an orphan drug designation to AmideBio’s glucagon analog (ABG-023) for the treatment of congenital hyperinsulinism (CHI). ABG-023 is a solution stable, soluble glucagon analog designed to overcome the limitations of glucagon – […]

  • AMIDEBIO Awarded $1.56M SBIR Phase II Grant to Further Development of its Novel Glucagons for the Treatment of Hyperinsulinism2019-09-30 - 07:33

    AmideBio, LLC, a privately held biopharmaceutical company, announced today that it has received $1.56M in funding through a Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The goal of this two-year grant is to enable an Investigational New Drug (IND) filing with the […]

  • David Brunel Takes Over Chairmanship at AmideBio2018-11-16 - 08:47

    AmideBio LLC, a privately held biopharmaceutical company, announced today that David Brunel, a board member of AmideBio, has assumed the role of Chairman of the Board, replacing Misha Plam. Dr. Plam, a founder of AmideBio who retired recently as President and CEO, is now Chairman Emeritus. Read the full press release.

Scroll to top